News From Industry Sources
Actavis receives approval of Fentanyl Transdermal System in the U.S.
August 21, 2007
Administration to market Fentanyl Transdermal System (a generic equivalent of Alza/Janssen's Duragesic(R) and available in 25, 50, 75 and 100 mcg/hour strengths. Story
New data suggest Cymbalta(R) reduced pain in fibromyalgia patients with and without depression
August 21, 2007
New data suggest that patients with fibromyalgia treated with 60mg or 120mg of Cymbalta(R) (duloxetine HCl) experienced greater reduction in pain severity beginning
one week after starting duloxetine than those taking placebo Story
Watson receives FDA approval for generic Duragesic(R)
August 21, 2007
WatsonPharmaceuticals, Inc announced today that it has received final approval from the
United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated
New Drug Application (ANDA) for fentanyl transdermal system in the 25, 50,
75 & 100 mcg/hour strengths Story
Ranbaxy receives approval to manufacture and market Hydrocodone Bitartrate and Acetaminophen Tablets USP
August 21, 2007
Ranbaxy Pharmaceuticals Inc. announced today that RLL has received approval from the U.S. Food and Drug Administration to manufacture and market Hydrocodone Bitartrate and Acetaminophen Tablets USP, 7.5 mg/750 mg, 10 mg/500 mg, 5 mg/500 mg, and 10 mg/325 mg strengths Story
Alpharma to market first topical NSAID patch in the U.S.
August 21, 2007
Alpharma Inc. (NYSE: ALO) today announced it had obtained exclusive license and distribution rights to market the FlectorŽ Patch, the first prescription topical NSAID (non-steroidal anti-inflammatory drug) patch approved by the FDA in the United States. The FlectorŽ Patch, which delivers the anti-inflammatory and analgesic effects of patent-protected diclofenac epolamine, is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. Story
Anodyne therapy peer-reviewed study demonstrates reduction in pain and pain medication use
August 20, 2007
Patients treated with Anodyne Therapy and physical therapy demonstrated a 64% reduction overall in their foot and leg pain. Prior to treatment, 74% of the patients experienced significant pain despite taking pain medications Story
Actavis receives approval generic Inderal(R) LA capsules in the U.S.
August 14, 2007
Actavis Group announced that it has received approval from the U.S. Food & Drug Administration to market Propranolol Hydrochloride extended-release capsules, which are indicated for the treatment of high blood pressure, long-term management of angina pectoris and prophylaxis of common migraine headaches. Story
|
